Identification of GM1-Ganglioside Secondary Accumulation in Fibroblasts from Neuropathic Gaucher Patients and Effect of a Trivalent Trihydroxypiperidine Iminosugar Compound on Its Storage Reduction

Costanza Ceni,Francesca Clemente,Francesca Mangiavacchi,Camilla Matassini,Rodolfo Tonin,Anna Caciotti,Federica Feo,Domenico Coviello,Amelia Morrone,Francesca Cardona,Martino Calamai

DOI: https://doi.org/10.3390/molecules29020453

IF: 4.6

2024-01-18

Molecules

Abstract:Gaucher disease (GD) is a rare genetic metabolic disorder characterized by a dysfunction of the lysosomal glycoside hydrolase glucocerebrosidase (GCase) due to mutations in the gene GBA1, leading to the cellular accumulation of glucosylceramide (GlcCer). While most of the current research focuses on the primary accumulated material, lesser attention has been paid to secondary storage materials and their reciprocal intertwining. By using a novel approach based on flow cytometry and fluorescent labelling, we monitored changes in storage materials directly in fibroblasts derived from GD patients carrying N370S/RecNcil and homozygous L444P or R131C mutations with respect to wild type. In L444P and R131C fibroblasts, we detected not only the primary accumulation of GlcCer accumulation but also a considerable secondary increase in GM1 storage, comparable with the one observed in infantile patients affected by GM1 gangliosidosis. In addition, the ability of a trivalent trihydroxypiperidine iminosugar compound (CV82), which previously showed good pharmacological chaperone activity on GCase enzyme, to reduce the levels of storage materials in L444P and R131C fibroblasts was tested. Interestingly, treatment with different concentrations of CV82 led to a significant reduction in GM1 accumulation only in L444P fibroblasts, without significantly affecting GlcCer levels. The compound CV82 was selective against the GCase enzyme with respect to the β-Galactosidase enzyme, which was responsible for the catabolism of GM1 ganglioside. The reduction in GM1-ganglioside level cannot be therefore ascribed to a direct action of CV82 on β-Galactosidase enzyme, suggesting that GM1 decrease is rather related to other unknown mechanisms that follow the direct action of CV82 on GCase. In conclusion, this work indicates that the tracking of secondary storages can represent a key step for a better understanding of the pathways involved in the severity of GD, also underlying the importance of developing drugs able to reduce both primary and secondary storage-material accumulations in GD.

chemistry, multidisciplinary,biochemistry & molecular biology

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on two aspects:

1. **Identifying the secondary accumulation of GM1 ganglioside in fibroblasts of patients with neuropathic Gaucher disease**:
- Gaucher Disease (GD) is a rare hereditary metabolic disorder, characterized by the dysfunction of lysosomal glycoside hydrolase glucocerebrosidase (GCase) due to mutations in the GBA1 gene, which in turn causes the accumulation of intracellular glucosylceramide (GlcCer). Most current studies mainly focus on the primary accumulated substances, while less attention is paid to the secondary stored substances and their interactions.
- By using new methods based on flow cytometry and fluorescent labeling, the researchers monitored the changes in stored substances in fibroblasts derived from GD patients carrying N370S/RecNcil and homozygous L444P or R131C mutations, relative to wild - type cells. In L444P and R131C fibroblasts, not only the primary accumulation of GlcCer was detected, but also a significant secondary increase in GM1 ganglioside was observed, which was comparable to the levels in patients with infantile GM1 gangliosidosis.

2. **Evaluating the effect of trivalent trihydroxypiperidine iminosugar compound (CV82) on the reduction of stored substances in L444P and R131C fibroblasts**:
- CV82 is a compound that has previously been shown to have good pharmacological chaperone activity for the GCase enzyme. The study tested the effect of treatment with different concentrations of CV82 on the levels of stored substances in L444P and R131C fibroblasts. The results showed that treatment with different concentrations of CV82 significantly reduced the GM1 accumulation in L444P fibroblasts, but had no significant effect on the GlcCer level.
- Further research indicates that the direct effect of CV82 on β - galactosidase (responsible for the degradation of GM1 ganglioside) is limited, suggesting that the reduction in GM1 may be related to other unknown mechanisms that are secondary to the direct effect of CV82 on GCase.

In conclusion, this paper aims to provide a basis for further understanding the pathogenesis of Gaucher disease and developing new treatment methods by identifying and evaluating the accumulation of secondary stored substances (such as GM1 ganglioside) and their response to drug treatment.